2022
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies
Brown S, Lavery J, Shen R, Martin A, Kehl K, Sweeney S, Lepisto E, Rizvi H, McCarthy C, Schultz N, Warner J, Park B, Bedard P, Riely G, Schrag D, Panageas K, Sweeney S, Foti M, Khotskaya Y, Fiandalo M, Gross B, Schultz N, Mastrogiacomo B, Sarmardy M, Li M, Resnick A, Waanders A, Lilly J, Carvajal R, Rabadan R, Ingham M, Hsaio S, Abraham J, Brenton J, Rueda O, Caldas C, Valgañón M, Silva D, Boursnell C, Garcia R, Rodriguez E, Nimmervoll B, Cerami E, Ducar M, Kumari P, Lindeman N, MacConnaill L, Orechia J, Schrag D, Shivdasani P, Van Allen E, Johnson J, Jänne P, Lepisto E, Hassett M, Pimentel S, Sripakdeevong P, Janeway K, Johnson J, Meyerson M, Quinn D, Cushing O, Haigis K, Miller D, Kehl K, Gustav A, Tramontano A, Baquero S, Bell J, Green M, McCall S, Datto M, Calvo F, Andre F, Guillaume M, Dogan S, Ludovic L, Scoazec J, Ardenos M, Vassal G, Michels S, Velculescu V, Baras A, Gocke C, Brahmer J, Sawyers C, Solit D, Gardos S, Berger M, Ladanyi M, Riely G, Sirintrapun J, Panageas K, Caroline A, Thomas S, Zarski A, Zehir A, Iasonosa A, Philip J, Brown S, Kung A, Kundra R, Rudolph J, Lavery J, Rivzi H, Schwartz J, McCarthy C, Bhuiya M, Martin A, Chu C, DuBois R, van de Velde T, Meijer G, Horlings H, van Tinteren H, Lolkema M, Nijman L, Bierkens M, Hoeve J, Voest E, Hiemstra A, Sonke G, Craenmehr J, Hudecek J, Monkhorst K, Urba W, Bernard B, Piening B, Bifulco C, Tittel P, Cramer J, Guinney J, Yu T, Guo X, Acebedo A, Gold P, Bailey N, Kadri S, Segal J, Pankhuri W, Wang P, George S, Christine M, Van't Veer L, Talevich E, Wren A, Sweet-Cordero A, Turski M, Bedard P, KamelReid S, Lu Z, Pugh T, Siu L, Watt S, Leighl N, Yu C, Ahmed L, Krishna G, Virtaenen C, Chow H, Plagianakos D, Del Rossi S, Singaravelan N, Hakgor S, Qazi N, Nguyen A, Stickle N, Stricker T, Micheel C, Anderson I, Jones L, Wang L, Lovly C, LeNoue Newton M, Park B, Warner J, Fabbri D, Coco J, Ye C, Chaugai S, Mishra S, Yang Y, Wen L, Dienstmann R, Aguilar Izquierdo S, Viaplana Donato C, Mancuso F, Topaloglu U, Liu L, Guan M, Zhang W, Jin G, Knight J, D'Eletto M, Ormay E, Mane S, Bilguvar K, Zenta W, Dykas D. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies. JAMA Oncology 2022, 8: 287-291. PMID: 34734967, PMCID: PMC9190030, DOI: 10.1001/jamaoncol.2021.5153.Peer-Reviewed Original ResearchConceptsOverall survivalStage IV non-small cell lung cancerNon-small cell lung cancerStage IV colorectal cancerUnadjusted median survivalCell lung cancerMedian survivalStudy entryCancer outcomesColorectal cancerLung cancerMolecular testingSurvival analysisGeneralizable research findingsClinical genomic studiesSurvivalCancerSelection biasAppropriate statistical methodsDiagnosisAmerican Association
2021
Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer
Kehl K, Riely G, Lepisto E, Lavery J, Warner J, LeNoue-Newton M, Sweeney S, Rudolph J, Brown S, Yu C, Bedard P, Schrag D, Panageas K, Sweeney S, Foti M, Khotskaya Y, Fiandalo M, Gross B, Schultz N, Mastrogiacomo B, Sarmardy M, Li M, Resnick A, Waanders A, Lilly J, Carvajal R, Rabadan R, Ingham M, Hsaio S, Abraham J, Brenton J, Rueda O, Caldas C, Valgañón M, Silva D, Boursnell C, Garcia R, Rodriguez E, Nimmervoll B, Cerami E, Ducar M, Kumari P, Lindeman N, MacConnaill L, Orechia J, Schrag D, Shivdasani P, Van Allen E, Johnson J, Jänne P, Lepisto E, Hassett M, Pimentel S, Sripakdeevong P, Janeway K, Johnson J, Meyerson M, Quinn D, Cushing O, Haigis K, Miller D, Kehl K, Gustav A, Tramontano A, Baquero S, Bell J, Green M, McCall S, Datto M, Calvo F, Andre F, Guillaume M, Dogan S, Ludovic L, Scoazec J, Ardenos M, Vassal G, Michels S, Velculescu V, Baras A, Gocke C, Brahmer J, Sawyers C, Solit D, Gardos S, Berger M, Ladanyi M, Riely G, Sirintrapun J, Caroline A, Thomas S, Zarski A, Zehir A, Iasonosa A, Philip J, Brown S, Kung A, Kundra R, Rudolph J, Lavery J, Rivzi H, Schwartz J, McCarthy C, Bhuiya M, Martin A, Chu C, DuBois R, van de Velde T, Meijer G, Horlings H, van Tinteren H, Lolkema M, Nijman L, Bierkens M, Hoeve J, Voest E, Hiemstra A, Sonke G, Craenmehr J, Hudecek J, Monkhorst K, Urba W, Bernard B, Piening B, Bifulco C, Tittel P, Cramer J, Guinney J, Yu T, Guo X, Acebedo A, Gold P, Bailey N, Kadri S, Segal J, Pankhuri W, Wang P, George S, Christine M, Van't Veer L, Talevich E, Wren A, Sweet-Cordero A, Turski M, Bedard P, KamelReid S, Lu Z, Pugh T, Siu L, Watt S, Leighl N, Yu C, Ahmed L, Krishna G, Virtaenen C, Chow H, Plagianakos D, Del Rossi S, Singaravelan N, Hakgor S, Qazi N, Nguyen A, Stickle N, Stricker T, Micheel C, Anderson I, Jones L, Wang L, Lovly C, LeNoue Newton M, Park B, Warner J, Fabbri D, Coco J, Ye C, Chaugai S, Mishra S, Yang Y, Wen L, Dienstmann R, Aguilar Izquierdo S, Viaplana Donato C, Mancuso F, Topaloglu U, Liu L, Guan M, Zhang W, Jin G, Knight J, D'Eletto M, Ormay E, Mane S, Bilguvar K, Zenta W, Dykas D. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer. JAMA Network Open 2021, 4: e2117547. PMID: 34309669, PMCID: PMC8314138, DOI: 10.1001/jamanetworkopen.2021.17547.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCandidate surrogate end pointsProgression-free survivalSurrogate end pointsOverall survivalTreatment discontinuationColorectal cancerEnd pointCohort studyNext treatmentNon-small cell lungRetrospective cohort studyAlternative end pointsCell lung cancerKey end pointsAdvanced diseasePrimary outcomeSystemic therapyCell lungLung cancerProlonged survivalMAIN OUTCOMEProgression eventsAcademic centersPatients
2015
Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, Köksal Y, Li J, Serin Harmancı A, Clark V, Carrión-Grant G, Baranoski J, Çağlar C, Barak T, Coşkun S, Baran B, Köse D, Sun J, Bakırcıoğlu M, Moliterno Günel J, Pamir MN, Mishra-Gorur K, Bilguvar K, Yasuno K, Vortmeyer A, Huttner AJ, Sander C, Günel M. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology 2015, 17: 1356-1364. PMID: 25740784, PMCID: PMC4578578, DOI: 10.1093/neuonc/nov027.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasSomatic POLE mutationsPOLE mutationsMalignant high-grade gliomasLonger progression-free survivalProgression-free survivalSomatic mutationsOverall survivalPediatric patientsBetter prognosisClinical featuresImproved prognosisClinical behaviorImmune cellsBizarre cellsAggressive formGlioblastoma multiformeDisease pathophysiologyMolecular subgroupsHomozygous germline mutationGermline mutationsPrognosisGlioma subtypesComprehensive genomic analysisDistinct subgroups